Daniël Blockmans

Universitair Ziekenhuis Leuven — Belgium

Medicine · Health Sciences

57h-index16.2kcitations363works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Vasculitis and related conditions(148), Otitis Media and Relapsing Polychondritis(50), Systemic Lupus Erythematosus Research(47), Systemic Sclerosis and Related Diseases(45), Coagulation, Bradykinin, Polyphosphates, and Angioedema(43)

Publications363 total

Efficacité et tolérance d’upadacitinib dans l’artérite à cellules géantes : résultats à 2 ans de l’essai de phase 3 randomisé et en double aveugle SELECT-GCA
Revue du Rhumatisme·2025
Reply to: Use of upadacitinib in giant cell arteritis
Clinical and Experimental Rheumatology·2025Open Access
The TFIID complex is a new autoantibody target in systemic sclerosis
Annals of the Rheumatic Diseases·2025Open Access
A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis
New England Journal of Medicine·2025· 48 citedOpen Access
Why, how and when to look for occult giant cell arteritis in patients with polymyalgia rheumatica
Lara D. Veeken·2025· 2 cited
Highlights from the breakout session: imaging in disease assessment
Lara D. Veeken·2025Open Access
Direct comparison of the diagnostic accuracy of PET/CT, cranial MRI, ultrasound and temporal artery biopsy in giant cell arteritis
European Journal of Nuclear Medicine and Molecular Imaging·2025· 2 cited
Validation of the polymyalgia rheumatica-activity score: A prospective cohort study
Seminars in Arthritis and Rheumatism·2025
Nodular Scleritis as Isolated Symptom of IgG4-Related Disease, Mimicking as Conjunctival Lymphoma: A Case Report
Case Reports in Ophthalmology·2025Open Access
External validation of the polymyalgia rheumatica impact scale: a prospective cohort study
Rheumatology Advances in Practice·2025· 1 citedOpen Access
Efficacité et tolérance d’upadacitinib chez des patients atteints d’artérite à cellules géantes (SELECT-GCA) : essai de phase III contrôlé et randomisé en double aveugle
Revue du Rhumatisme·2024· 2 cited
Large vessel vasculitis is a risk factor for relapse only in giant cell arteritis patients without polymyalgia rheumatica
Lara D. Veeken·2024· 1 cited
Polymyalgia rheumatica is a risk factor for more recalcitrant disease in giant cell arteritis: A retrospective cohort study
Seminars in Arthritis and Rheumatism·2024
LBA0001 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
Annals of the Rheumatic Diseases·2024· 13 cited
Comparison of symptoms between diagnosis and relapse in giant cell arteritis: a retrospective cohort study
Lara D. Veeken·2024· 5 citedOpen Access
Prevalence and outcome of occult giant cell arteritis
European Journal of Internal Medicine·2024· 1 cited
VEXAS syndrome: Focus on dermatological manifestations and their histopathological correlate
JEADV Clinical Practice·2024Open Access
Prevalence, characteristics, and outcome of subclinical vasculitis in polymyalgia rheumatica: a retrospective cohort study
Lara D. Veeken·2024· 11 citedOpen Access
Association between vascular FDG uptake during follow-up and the development of thoracic aortic aneurysms in giant cell arteritis
Frontiers in Medicine·2024· 11 citedOpen Access
Corrigendum to “Epidemiology and predictors of relapse in giant cell arteritis: A systematic review and meta-analysis” [Joint Bone Spine 2023;90 :105494]
Joint Bone Spine·2024· 2 cited
page 1 of 19Next →

Frequent Co-authors

María C. Cid(10), David Jayne(9), Elisabeth Brouwer(8), Bhaskar Dasgupta(8), Loı̈c Guillevin(7), Frédéric Houssiau(6), Alfred Mahr(6), Herman Bobbaers(6), Xavier Bossuyt(6), Carlo Salvarani(5), Sebastian Unizony(5), Carlos Vasconcelos(5), Haner Di̇reskeneli̇(5), Renato Alberto Sinico(5), Geneviève Depresseux(5), Ricard Cervera(5), Luc Mouthon(5), Steven Vanderschueren(5), Augusto Vaglio(5), John H. Stone(4)